Drug Approval | April 17, 2025
Lupin receives EIR from USFDA for its injectable facility in Nagpur
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Deflazacort is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older
The company does not expect this development to have any material impact on the current business operations
_256_384.jpg)
Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and metastatic adenocarcinoma of the pancreas
Jobevne is a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks the interaction with its receptors to prevent angiogenesis
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Sumitomo Chemical began its nucleic acid drug substance contract manufacturing business in 2013
Subscribe To Our Newsletter & Stay Updated
